Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small-molecule. It is engaged in discovering and developing small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, Mutation-Allostery-Pharmacology, which targets cancer mutations.Black Diamond focuses on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes. It also targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 29, 2022 | Series Unknown | $10M | — | — | — | Detail |
Jan 29, 2020 | IPO | $231.30M | — | — | — | Detail |
Dec 5, 2019 | Series C | $85M | 13 |
![]() |
— | Detail |
Jan 9, 2019 | Series B | $85M | 14 |
![]() ![]() ![]() |
— | Detail |
Dec 12, 2018 | Series A | $20M | 1 |
![]() |
— | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 12, 2022
![]() |
Series A | $30M | Life Science | — |
Feb 8, 2021
![]() |
Seed | $4M | Consumer | — |
Mar 25, 2020
![]() |
Seed | $13M | Artificial Intelligence | — |
Apr 18, 2019
![]() |
Seed | $2.70M | Developer Tools | — |
Aug 4, 2016
![]() |
Series B | $15M | Electronic Health Record (EHR) | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series C |
![]() |
— | Series C |
![]() |
— | Series C |
|
— | Series C |
![]() |
— | Series C |
|
— | Series C |
![]() |
— | Series C |
|
— | Series C |
![]() |
— | Series C |
![]() |
— | Series C |